Research presented at this week’s ISPOR 2019 meeting sheds important light on the impact of biologics on the use of other healthcare resources.
Biologics have represented a major step forward in the treatment of inflammatory bowel disease, comprising both Crohn disease (CD) and ulcerative colitis (UC). Despite their benefits, biologics are high-cost therapies, and their expense is often cited as a challenge for healthcare systems worldwide. However, research presented at this week’s ISPOR 2019 meeting sheds important light on the impact of biologics on the use of other healthcare resources.
First, a research team from Brazil shared their findings that among patients with CD, surgery costs were lower among those using biologics than among those using small-molecule drugs (azathioprine and prednisolone).1
Using a Markov model, the investigators used a 100-patient cohort and calculated the number of surgeries undergone by the patients. They found that, on a 3-year time horizon, the total surgery-related costs for patients receiving small-molecule drugs were BRL $356,578 (approximately US $88,057).
By contrast, costs were as follows for patients receiving biologics: BRL $260,340 (approximately US $64,291) for ustekinumab, BRL $285,562 (approximately US $70,520) for adalimumab, BRL $290,246 (approximately US $71,676) for certolizumab pegol, and BRL $319,628 (approximately US $78,932) for vedolizumab.
Another study found that, among patients with UC, use of biologics is on the rise, and use of corticosteroids and opioids decreased among patients who were treated with biologics.2
The study analyzed medication use and healthcare resource utilization among patients with UC in the United States between 2007 and 2017. Adults with 1 or more UC diagnostic codes were included in the retrospective analysis of medical and pharmacy claims data.
The investigators found that, during the study period, the prevalence of biologic therapy among patients with UC rose from 1.9% to 12.5%. While overall corticosteroid use increased from 28.6% to 31.1%, among biologic users, corticosteroid use dropped from 60.5% to 47.2%. Opioid use also dropped from 53.6% to 40.3% among patients receiving biologics.
Continued collection of real-world data, say the authors, is necessary to capture changes in healthcare resource utilization, as well as cost, as the UC treatment landscape continues to evolve.
References
1. Santos MCLD, Rosim RP, Rachid ML, Fioratti C, Decimoni TC, Brunelli MJ. Surgery-related costs averted by the use of biologic drugs for the treatment of Crohn’s disease from the Brazilian private healthcare system perspective calculated through a mathematical model. Presented at: International Society for Pharmacoeconomics and Outcomes Research 24th Annual International Meeting; May 18-22, 2019; New Orleans, Louisiana. Abstract PGI9.
2. Hunter T, Farrar M, Dong Y, Choong C, Naegeli A. Medication use and healthcare resource utilization trends among adults ulcerative colitis patients in the United States—2007-2017. Presented at: International Society for Pharmacoeconomics and Outcomes Research 24th Annual International Meeting; May 18-22, 2019; New Orleans, Louisiana. Abstract PGI13.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.